Assessment of Chilbains Occuring During Covid-19 Infection

COVID Clinical Trial

— ChilblainCOVID  

Official title:

Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04344119
• Other study ID #: 20dermatocovid01
• Status: Recruiting
• Start date: April 9, 2020
• Est. completion date: April 30, 2021

Study information

• Verified date: April 2020
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Cynthia CAILLON
• Phone: +33492034011
• Email: caillon.c[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. These acral manifestation could be due to a direct viral effect, but also to microthrombosis or vascularitis. Understanding the pathomechanisms involved could provide interesting clue for understanding not only the skin manifestations but also some of the other systemic symptoms associated to covid-19 infection. This study plan to characterize these acral manifestations by analyzing the clinical and dermoscopic patterns and to correlate them with the non-invasive vascular explorations but also immune and coagulopathy explorations that are done in the CHU of Nice in covid-19 patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: April 30, 2021
• Est. primary completion date: April 30, 2021
• Gender: All
• Age group: N/A to 90 Years

Eligibility

Inclusion Criteria:

• All patients with proven covid infection (using PCR, serum antibody or lung TDM) and presenting at least one cutaneous lesions that occurred during the infection.

Related Conditions & MeSH terms

• Chilblains
• COVID
• Skin Manifestations

Locations

Country	Name	City	State
France	CHU de Nice	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical skin manifestations	Type and description of the skin manifestations with a special focus on patients with chilblains	3 months
Secondary	Histology and biological data	Data on Histology (HE staining and immunofluorescence) and on biology (blood cells counts, CRP and immune profile) will be collected in covid patient with skin manifestation	3 months
Secondary	Non invasive vascular examination	Vascular examination will be performed by Capillaroscopy, laser-doppler or lung TDM if clinically required	3 months